Previous 10 | Next 10 |
Alexion Pharmaceuticals (ALXN): Q1 Non-GAAP EPS of $3.52 beats by $0.38; GAAP EPS of $2.86 beats by $0.30.Revenue of $1.64B (+13.9% Y/Y) beats by $60M.Shares +2.3% PM.Press Release For further details see: Alexion Pharmaceuticals EPS beats by $0.38, beats on revenue
1Q21 total revenues of $1,636.5 million, a 13% increase over 1Q20 1Q21 GAAP diluted EPS of $2.86; non-GAAP diluted EPS of $3.52 Completed enrollment in Phase 3 studies of ULTOMIRIS ® (ravulizumab) in NMOSD and ALS Filed for regulatory approval of ONDEX...
Alexion Pharmaceuticals (NASDAQ:ALXN) is scheduled to announce Q1 earnings results on Friday, April 30th, before market open.The consensus EPS Estimate is $3.14 (-2.5% Y/Y) and the consensus Revenue Estimate is $1.58B (+9.7% Y/Y).Over the last 2 years, ALXN has beaten EPS estimates 100% of th...
[[ABBV]], [[ALXN]], [[AON]], [[AVNT]], [[AZN]], [[B]], [[BCPC]], [[CBOE]], [[CHTR]], [[CL]], [[CLX]], [[CRI]], [[CVX]], [[GT]], [[GWW]], [[HRC]], [[HUN]], [[IMO]], [[ITW]], [[JCI]], [[JELD]], [[LAZ]], [[LHX]], [[LYB]], [[MGP]], [[MOG.A]], [[NWL]], [[PBI]], [[PFS]], [[PNM]], [[POR]], [[PSX]], ...
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the first quarter ended March 31, 2021 before the US financial markets open on April 30, 2021, rather than on May 3, 2021 as previously announced. Given the previously...
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) traded today at a new 52-week high of $166.71. This new high was reached on below average trading volume as 866,000 shares traded hands, while the average 30-day volume is approximately 2.4 million shares. Alexion Pharmaceuticals Inc. (NASDAQ:AL...
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the first quarter ended March 31, 2021 before the US financial markets open on May 3, 2021. Given the previously announced agreement to be acquired by AstraZeneca, Ale...
Shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) traded today at $165.73, eclipsing its 52-week high. This new high was reached on below average trading volume as 866,000 shares traded hands, while the average 30-day volume is approximately 2.4 million shares. Alexion Pharmaceuticals...
The S&P 500 Health Care index has returned ~6.9% so far this year lagging the ~11.4% gain in the overall index.The underperformance ‘belies the reality’ that the sector which accounts for ~18% of the national gross domestic product, has mostly returned to normal after months...
Merger activity increased last week with six new deals announced. $50 billion worth of deals announced in a single week. Thermo Fisher Scientific to acquire PPD Inc. For further details see: Merger Arbitrage Mondays - Microsoft's Acquisition Of Nuance Offers A 5% Spread ...
News, Short Squeeze, Breakout and More Instantly...
Alexion Pharmaceuticals Inc. Company Name:
ALXN Stock Symbol:
NASDAQ Market:
Alexion Pharmaceuticals Inc. Website:
AstraZeneca (NASDAQ: AZN) hopes to soon close its planned acquisition of Alexion Pharmaceuticals (NASDAQ: ALXN) . The only hurdle left to jump is obtaining approval from United Kingdom regulators. In this Motley Fool Live video recorded on July 7 , Motley Fool contri...
This week, pharma and biotech giant AstraZeneca (NASDAQ: AZN) cleared its final hurdle in the proposed acquisition of orphan drug pharma company Alexion Pharmaceuticals (NASDAQ: ALXN) when it announced that the deal had received clearance from the United Kingdom's Compet...